Showing 301-310 of 9072 results for "".
The ESOP Model: An Alternative to PE for Dermatology Practices
https://practicaldermatology.com/issues/september-2025/the-esop-model-an-alternative-to-pe-for-dermatology-practices/37637/Not all practice models are as simple as private practice vs private equity. At Ada West Dermatology in Boise, Idaho, we’ve adopted a somewhat uncommon business model called an employee stock ownership plan (ESOP) and it’s worked very well for us.The Benefits of Private Practice: A Q&A with Joel Schlessinger, MD, FAAD
https://practicaldermatology.com/issues/september-2025/the-benefits-of-private-practice-a-qa-with-joel-schlessinger-md-faad/37630/While selling to and working for private equity–backed platforms may have its perks, many long-time private practitioners warn that the advantages of private practice are often not fully appreciated until it is too late. Practical Dermatology Chief Cosmetic Surgery Editor Emeritus Joel Schlessinger,Mergers and Acquisitions in Derm and Aesthetics: Market Outlook
https://practicaldermatology.com/issues/september-2025/mergers-and-acquisitions-in-derm-and-aesthetics-market-outlook/37631/We took a deeper look into the dermatology and aesthetics mergers and acquisitions (M&A) market in a conversation with two of our team members, Drew Thomas and Jordan Frickle, who are closely involved in this sector. The following discussion brings together their perspectives on current trends,Cutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occuAccess Is Everything
https://practicaldermatology.com/topics/practice-management/access-is-everything/23942/The Safe Step Act of 2023 seeks to rein in fail-first policies and protect patients.How May Biosimilars Affect the Treatment of Psoriasis?
https://practicaldermatology.com/topics/psoriasis/how-may-biosimilars-affect-the-treatment-of-psoriasis/23867/The answer depends on several factors.Cognitive Bias And The Art of Doctoring
https://practicaldermatology.com/topics/practice-management/cognitive-bias-and-the-art-of-doctoring/23680/Rethinking the approach to diagnosis may reduce errors and improve patient interactions.Examining the Emotional Impact of Acne in a Virtual World
https://practicaldermatology.com/columns/clinical-focus-1/examining-the-emotional-impact-of-acne-in-a-virtual-world/23577/Acne patients are working hard to conceal their acne on Zoom.Checkpoint Blockade for Advanced cSCC: Exploring Newer Options
https://practicaldermatology.com/topics/skin-cancer-photoprotection/checkpoint-blockade-for-advanced-cscc-exploring-newer-options/23487/Two newer systemic options on the market provide hope in the fight against advanced cutaneous squamous cell carcinoma.Six Financial Actions to Take During the COVID-19 Crisis
https://practicaldermatology.com/topics/practice-management/six-financial-actions-to-take-during-the-covid-19-crisis/23293/Tips to help weather the storm and prepare for better days ahead.